The healthcare equity landscape suggests BMY stock forecast 2025 will track upward momentum if FDA clearance for its hematology assets arrives within Q2–Q3 timelines. Market participants will be closely following the financial results of Bristol Myers Squibb in its upcoming release. The company plans to announce its earnings on October 30, 2025. The company is predicted to post an EPS of $1.65, indicating a 8.33% decline compared to the equivalent quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $11.77 billion, indicating a 1.03% downward movement from the same quarter last year. Bristol-Myers Squibb’s stock prices soared 5.9% after the release of its impressive Q3 results on Oct. 31. Driven by the increase in sales of its Growth Portfolio and Eliquis, BMY’s total revenues surged 8.4% year-over-year to $11.9 billion which surpassed the Street’s expectations by over 5%. Although its adjusted net earnings declined 11.8% year-over-year to approximately $3.7 billion, its adjusted EPS of $1.80 surpassed the consensus estimates by a staggering 20.8%. Market sentiment toward BMY remains cautiously bullish going into 2025, with dividend yields consistently above 3%, reinforcing investor appetite for defensive healthcare plays.